Small interfering RNA library screen identified polo-like kinase-1 (PLK1) as a potential therapeutic target for breast cancer that uniquely eliminates tumor-initiating cells

Breast Cancer Research

Volumn 14, Issue 1, 2012, Pages

  Hu, Kaiji ^a   Law, Jennifer H ^a   Fotovati, Abbas ^a   Dunn, Sandra E ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (8 CYCLOPENTYL 7 ETHYL 5,6,7,8 TETRAHYDRO 5 METHYL 6 OXO 2 PTERIDINYLAMINO) 3 METHOXY N (1 METHYL 4 PIPERIDINYL)BENZAMIDE; DOXORUBICIN; FLUOROURACIL; HERMES ANTIGEN; PACLITAXEL; POLO LIKE KINASE 1; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CCNB1 PROTEIN, HUMAN; CD44 PROTEIN, HUMAN; CELL CYCLE PROTEIN; CYCLIN B1; ONCOPROTEIN; POLO-LIKE KINASE 1; PROTEIN SERINE THREONINE KINASE; PTERIDINE DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL CULTURE; CELL GROWTH; CELL SUBPOPULATION; CONTROLLED STUDY; GENETIC SCREENING; GROWTH INHIBITION; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CANCER STEM CELL; CELL PROLIFERATION; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; FEMALE; GENE EXPRESSION; GENE LIBRARY; GENE SILENCING; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; RNA INTERFERENCE; TUMOR CELL LINE;

ANTIGENS, CD44; ANTINEOPLASTIC AGENTS; APOPTOSIS; BREAST NEOPLASMS; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CELL PROLIFERATION; CYCLIN B1; DOXORUBICIN; FEMALE; FLUOROURACIL; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE LIBRARY; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; PACLITAXEL; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PTERIDINES; RNA INTERFERENCE; RNA, SMALL INTERFERING;

EID: 84856575716     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3107     Document Type: Article

References (56)

1. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenchikov A, Williams C, Zhu SX, Lønning PE, Børreson-Dale AL, Brown PO, Botstein D. Molecular portraits of human breast tumours. Nature 2000, 406:747-752. 10.1038/35021093, 10963602.
2. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Eystein Lønning P, Børresen-Dale AL. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 2001, 98:10869-10874. 10.1073/pnas.191367098, 58566, 11553815.
3. Dent R, Trudeau M, Pritchard KL, Hanna WM, Kahn HK, Sawka CA, Lickley LA, Rawlinson E, Sun P, Narod SA. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res 2007, 13:4429-4434. 10.1158/1078-0432.CCR-06-3045, 17671126.
4. Chacon RD, Costanzo MV. Triple negative breast cancer. Breast Cancer Res 2010, 12(Suppl 2):S3. 3005723, 21172087.
5. de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011, 137:183-192. 10.1007/s00432-010-0957-x, 3018596, 21069385.
6. Fong PC, Boss DS, Yap TA, Tutt A, Wu P, Mergui-Roelvink M, Mortimer P, Swasiland H, Lau A, O'Connor MJ, Ashworth A, Carmichael J, Kaye SB, Schellens JH, de Bono JS. Inhibition of poly(ADP-ribosa) polymerase in tumors from BRCA mutation carriers. N Engl J Med 2009, 361:123-134. 10.1056/NEJMoa0900212, 19553641.
7. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poly (ADP-ribose) polymerase. Nature 2005, 434:913-917. Erratum, Nature 2007, 447:346, 10.1038/nature03443, 15829966.
8. Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM. Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer. J Med Genet 2011, doi:10.1136/jmedgenet-2011-100006.
9. Santana-Davila R, Perez EA. Treatment options for patients with triple-negative breast cancer. J Hematol Oncol 2010, 3:42-52. 10.1186/1756-8722-3-42, 2987865, 20979652.
10. Wicha MS. Cancer stem cell heterogeneity in hereditary breast cancer. Breast Cancer Res 2008, 10:105-106. 10.1186/bcr1990, 2397530, 18423071.
11. Charafe-Jauffret E, Ginestier C, Birnbaum D. Breast cancer stem cells: tools and models to relay on. BMC Cancer 2009, 9:202-211. 10.1186/1471-2407-9-202, 2708191, 19555472.
12. Zhou BS, Zhang H, Damelin M, Geles KG, Grindley JC, Dirks PB. Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nature Rev Drug Discovery 2009, 8:806-823.
13. Sajithlal GB, Rothermund K, Zhang F, Dabbs DJ, Latimer JJ, Grant SG, Prochownik EV. Permanently blocked stem cells derived from breast cancer cell lines. Stem Cells 2010, 28:1008-1018. 10.1002/stem.424, 20506227.
14. To K, Zhao Y, Jiang H, Hu K, Wang M, Wu J, Lee C, Yokom DW, Stratford AL, Klinge U, Mertens PR, Chen CS, Bally M, Yapp D, Dunn SE. The phosphoinositide-dependent kinase-1 inhibitor, OSU-03012, prevents Y-box binding protein-1 (YB-1) from inducing epidermal growth factor receptor (EGFR). Mol Pharmacol 2007, 72:641-652. 10.1124/mol.107.036111, 17595327.
15. Fillmore CM, Kuperwasser C. Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy. Breast Cancer Res 2008, 10:R25. 10.1186/bcr1982, 2397524, 18366788.
16. Smith KM, Datti A, Fujitani M, Grinshtein N, Zhang L, Morozova O, Blakely KM, Rotenberg SA, Hansford LM, Miller FD, Yeger H, Irwin MS, Moffat J, Marra MA, Baruchel S, Wrana JL, Kaplan DR. Selective targeting of neuroblastoma tumour-initiating cells by compounds identified in stem cell-based small molecule screens. EMBO Mol Med 2010, 2:371-384. 10.1002/emmm.201000093, 20721990.
17. Lee HE, Kim JH, Kim YJ, Choi SY, Kim SW, Kang E, Chung IY, Kim IA, Kim EJ, Choi Y, Ryu HS, Park SY. An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer. Br J Cancer 2011, 104:1730-1738. 10.1038/bjc.2011.159, 21559013.
18. MacKeigan JP, Murphy LO, Blenis J. Sensitized RNAi screen of human kinases and phosphatases identifies new regulators of apoptosis and chemoresistance. Nature Cell Biol 2005, 7:591-600. 10.1038/ncb1258, 15864305.
19. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE. Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther 2009, 8:3024-3034. 10.1158/1535-7163.MCT-09-0365, 2783569, 19887553.
20. Bauer JA, Ye F, Marshall CB, Lehmann BD, Pendleton CS, Shyr Y, Arteaga CL, Pietenpol JA. RNA interference (RNAi) screen approach identifies agents that enhance paclitaxel activity in breast cancer cells. Breast Cancer Res 2010, 12:R41. 10.1186/bcr2595, 2917036, 20576088.
21. Cohen P. Protein kinases: the major drug targets of the twenty-first century?. Nature Rev Drug Discov 2002, 1:309-315.
22. Alvarez RH. Present and future evolution of advanced breast cancer therapy. Breast Cancer Res 2010, 12(Suppl 2):S1. 3005721, 21172071.
23. Speers C, Tsimelzon A, Sexton K, Herrick AM, Gutierrez C, Culhane A, Quackenbush J, Hilsenbeck S, Chang J, Brown P. Identification of novel kinase targets for the treatment of estrogen receptor-negative breast cancer. Clin Cancer Res 2009, 15:6327-6340. 10.1158/1078-0432.CCR-09-1107, 2763053, 19808870.
24. Stratford AL, Habibi G, Astanehe A, Jiang H, Hu K, Park E, Shadeo A, Buys TP, Lam W, Pugh T, Marra M, Nielsen TO, Klinge U, Mertens PR, Aparicio S, Dunn SE. Epidermal growth factor receptor (EGFR) is transcriptionally induced by the Y-box binding protein-1 (YB-1) and can be inhibited with Iressa in basal-like breast cancer, providing a potential target for therapy. Breast Cancer Res 2007, 9:R61. 10.1186/bcr1767, 2242657, 17875215.
25. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006, 444:756-760. 10.1038/nature05236, 17051156.
26. Grinshtein N, Datti A, Fujitani M, Uehling D, Prakesch M, Isaac M, Irwin MS, Wrana JL, Al-Awar R, Kaplan DR. Small molecule kinase inhibitor screen identifies polo-like kinase 1 as a target for neuroblastoma tumor-initiating cells. Cancer Res 2011, 71:1385-1395. 10.1158/0008-5472.CAN-10-2484, 21303981.
27. Prochownik EV, Lazo JS. Small molecule inhibitors of cancer stem cells. US Patent 2010, 20100298352.
28. Steegmaier M, Hoffmann M, Baum A, Lénárt P, Petronczki M, Krššák M, Gürtler U, Garin-Chesa P, Lieb S, Quant J, Grauert M, Adolf GR, Kraut N, Peters JM, Wolfgang J, Rettig WJ. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 2007, 17:316-322. 10.1016/j.cub.2006.12.037, 17291758.
29. Wu J, Lee C, Yokom D, Jiang H, Cheang MCU, Yorida E, Turbin D, Berquin IM, Mertens P, Iftner T, Gilks CB, Dunn SE. Disruption of the Y-box binding protein-1 results in suppression of the epidermal growth factor receptor and Her-2. Cancer Res 2006, 66:4872-4879. 10.1158/0008-5472.CAN-05-3561, 16651443.
30. To K, Fotovati A, Reipas KM, Law JH, Hu K, Wang J, Astanehe A, Davies AH, Lee L, Stratford AL, Raouf A, Johnson P, Berquin IM, Royer HD, Eaves CJ, Dunn SE. YB-1 induces expression of CD44 and CD49f leading to enhanced self-renewal, mammosphere growth, and drug resistance. Cancer Res 2010, 70:2840-2851. 10.1158/0008-5472.CAN-09-3155, 2848879, 20332234.
31. Abraham BK, Fritz P, McClellan M, Hauptvogel P, Athelogou M, Brauch H. Prevalence of CD44+/CD24-/low cells in breast cancer may not be associated with clinical outcome but may favor distant metastasis. Clin Cancer Res 2005, 11:1154-1159.
32. Spankuch B, Kurunci-Csacsko E, Kaufmann M, Strebhardt K. Rational combinations of siRNAs targeting plk1 with breast cancer drugs. Oncogene 2007, 26:5793-5807. 10.1038/sj.onc.1210355, 17369857.
33. Lorns E, Lord CJ, Turner N, Ashworth A. Utilizing RNA interference to enhance cancer drug discovery. Nature Rev 2007, 6:556-568.
34. Signoretti S, Di Marcotullio L, Richardson A, Ramaswamy S, Isaac B, Rue M, Monti F, Loda M, Pagano M. Oncogenic role of the ubiquitin ligase subunit Skp2 in human breast cancer. J Clin Invest 2002, 110:633-641. 151109, 12208864.
35. Sonoda H, Inoue H, Ogawa K, Utsunomiya T, Masuda TA, Mori M. Significance of skp2 expression in primary breast cancer. Clin Cancer Res 2006, 12:1215-1220. 10.1158/1078-0432.CCR-05-1709, 16489076.
36. Davidovich S, Ben-Izhak O, Shapira M, Futerman B, Hershko DD. Over-expression of Skp2 is associated with resistance to preoperative doxorubicin-based chemotherapy in primary breast cancer. Breast Cancer Res 2008, 10:R63. 10.1186/bcr2122, 2575536, 18644126.
37. de Castro PI, de Carcer G, Montoya G, Malumbres M. Emerging cancer therapeutic opportunities by inhibiting mitotic kinases. Curr Opin Pharmacol 2008, 8:375-383. 10.1016/j.coph.2008.06.013, 18644252.
38. Merry C, Fu K, Wang J, Yeh IJ, Zhang Y. Targeting the checkpoint kinase Chk1 in cancer therapy. Cell Cycle 2010, 9:279-283. 10.4161/cc.9.2.10445, 3048588, 20023404.
39. Casarsa C, Oriana S, Coradini D. The controversial clinicobiological role of breast cancer stem cells. J Oncol 2008, 2008:492643. ///, 2657953, 19325911.
40. Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nature Rev Cancer 2006, 6:321-330.
41. de Castro PI, de Carcer G, Malumbres M. A census of mitotic cancer genes: new insight into tumor cell biology and cancer therapy. Carcinogenesis 2007, 28:899-912.
42. Yuan J, Hörlin A, Hock B, Stutte HJ, Rübsamen-Waigmann H, Strebhardt K. Polo-like kinase, a novel marker for cellular proliferation. Am J Pathol 1997, 150:1165-1172. 1858156, 9094972.
43. Wolf G, Elez R, Doermer A, Holtrich U, Ackermann H, Stutte HJ, Altmannsberger HM, Rübsamen-Waigmann H, Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14:543-549. 10.1038/sj.onc.1200862, 9053852.
44. Kneisel L, Strebhardt K, Bernd A, Wolter M, Binder A, Kaufmann R. Expression of polo-like kinase (PLK1) in thin melanomas: a novel marker of metastatic disease. J Cutan Pathol 2002, 29:354-358. 10.1034/j.1600-0560.2002.290605.x, 12135466.
45. Ahr A, Holtrich U, Solbach C, Schar A, Strebhardt K, Karn T, Kaufmann M. Molecular classification of breast cancer patients by gene expression profiling. J Pathol 2001, 195:312-320. 10.1002/path.955, 11673828.
46. Ahr A, Karn T, Solbach C, Seiter T, Strebhardt K, Holtrich U, Kaufmann M. Identification of high risk breast-cancer patients by gene expression profiling. Lancet 2002, 359:131-132. 10.1016/S0140-6736(02)07337-3, 11809257.
47. Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe plk1 depletion. Mol Cell Biol 2006, 26:2093-2108. 10.1128/MCB.26.6.2093-2108.2006, 1430287, 16507989.
48. Degenhardt Y, Lampkin T. Targeting polo-like kinase in cancer therapy. Clin Cancer Res 2010, 16:384-389. 10.1158/1078-0432.CCR-09-1380, 20068088.
49. Schöffski P, Blay JY, De Greve J, Brain E, Machiels JP, Soria JC, Sleijfer S, Wolter P, Ray-Coquard I, Fontaine C, Munzert G, Fritsch H, Hanft G, Aerts C, Rapion J, Allgeier A, Bogaerts J, Lacombe D. Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma: The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI). Eur J Cancer 2010, 46:2206-2215. 10.1016/j.ejca.2010.03.039, 20471824.
50. Harrison MR, Holen KD, Liu G. Beyond taxanes: a review of novel agents that target mitotic tubulin and microtubules, kinases, and kinesins. Clin Adv Hematol Oncol 2009, 7:54-64. 2904974, 19274042.
51. Chopra P, Sethi G, Dastidar SG, Ray A. Polo-like kinase inhibitors: an emerging opportunity for cancer therapeutics. Expert Opin Investig Drugs 2010, 19:27-43. 10.1517/13543780903483191, 20001553.
52. Gleixner KV, Ferenc V, Peter B, Gruze A, Meyer RA, Hadzijusufovic E, Cerny-Reiterer S, Mayerhofer M, Pickl WF, Sillaber C, Valent P. Polo-like kinase 1 (Plk1) as a novel drug target in chronic myeloid leukemia: overriding imatinib resistance with the Plk1 inhibitor BI 2536. Cancer Res 2010, 70:1513-1523. 10.1158/0008-5472.CAN-09-2181, 20145140.
53. Bevan P, Mala C. The Role of uPA and uPA inhibitors in breast cancer. Breast Care (Basel) 2008, 3(Suppl 2):1-2.
54. Goldstein LJ. Experience in phase I trials and an upcoming phase II study with uPA inhibitors in metastatic breast cancer. Breast Care (Basel) 2008, 3(Suppl 2):25-28.
55. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, Goulet R, Badve S, Nakshatri H. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res 2006, 8:R59. 10.1186/bcr1610, 1779499, 17062128.
56. Balic M, Lin H, Young L, Hawes D, Giuliano A, McNamara G, Datar RH, Cote RJ. Most early disseminated cancer cells detected in bone marrow of breast cancer patients have a putative breast cancer stem cell phenotype. Clin Cancer Res 2006, 12:5615-5621. 10.1158/1078-0432.CCR-06-0169, 17020963.